Anavex Life Sciences Corp (AVXL)

[bas2020]

I couldn't get past the first nonsensical sentence of your FUDiatribe.

Missling knowing that the company did not meet all endpoints and have a likely fail in sight?

What a complete and utter fraud you are! You're getting more ridiculous by the day!

It's clear to real investors that the Cog & ADL ORs were presented in the first PR and CTAD to highlight the strong responders, along with stat. sig. Cog & CDR mean scores. It was the purpose of the presentation to demonstrate patient IMPROVEMENT in the trial, differentiating it from all other past AD P3 trials. That was clearly accomplished. Since the ORs were pre-specified in the SAP that data, along with CDR-SB, resulted in a successful trial that met all endpoints.

What the Sept 14 PR accomplished was not only to detail how ADAS-Cog and CDR-SB calculations alone (each with p< .025) make for an acceptable FDA trial result, but also identified 2 key biomarkers that will facilitate an AA pathway option. Whether ADCS-ADL had a p < .05 is now immaterial.

It's only the common FUDsters who keep trying to make an issue of ADL as they disregard all of the significant data that will lead to FDA approval, with the OLE likely becoming the confirmatory trial.